Netrin-1 and UNC5B as Novel Targets in Metabolic Liver Diseases: NAFLD & NASH
Innovative and effective therapies for treating Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH)
Chimeric FGF21: Treatment of NAFLD, NASH and Hepatic Steatosis
New and efficacious versions of fibroblast growth factor 21 (FGF21) for metabolic liver diseases